Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
🩺 Protocol Summary
The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).
Primary Research Facility: Xencor Investigative Site (Scottsdale, Arizona)
📋 Preliminary Self-Screener
0 of 3 AnsweredAnswer all 3 basic criteria below to see your preliminary screening result:
📍 Primary Site Map
Site: Xencor Investigative Site — Scottsdale, Arizona
📍 All Participating Trial Locations (90 Sites)
Multi-Center TrialThis protocol is enrolling participants across multiple clinical centers:
📄 Print Doctor Discussion Sheet
Preview and print a 1-page summary with 5 tailored questions for your physician.
💰 Clinical Trial Costs & Insurance Coverage
Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.
💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.